FDA
-
-
-
-
-
-
-
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Galectin presents NAVIGATE trial biomarker data at liver meeting
-
-
-
-
-
-
-
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
-
-
-
-
-
-
-
Galectin Therapeutics (GALT) Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
-
-
-
-
-
-
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
-
-
-
-
-
-
-
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
-
-
-
-
-
-
-
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
-
324,010 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

